<DOC>
	<DOCNO>NCT00096993</DOCNO>
	<brief_summary>This Phase II , randomize , placebo-controlled , double-blind , multicenter clinical trial pertuzumab combination gemcitabine relative placebo combination gemcitabine subject advance ovarian , primary peritoneal , fallopian tube cancer resistant platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study Evaluate rhuMab 2C4 Gemcitabine Subjects With Ovarian , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent Age &gt; = 18 year Advanced , histologically documented ovarian , primary peritoneal , fallopian tube carcinoma Representative tumor specimens paraffin block least 12 unstained slide associated pathology report , obtain time prior entry study evaluation HER2 activation Measurable disease least one lesion accurately measure least one dimension ( long dimension record ) , Or : Clinically radiologically detectable disease ( e.g. , ascites , peritoneal deposit , mesenteric thicken lesion fulfill RECIST measurable disease ) Platinumresistant refractory carcinoma Life expectancy &gt; = 12 week ECOG performance status 0 1 LVEF &gt; = 50 % , determine ECHO Use effective mean contraception ( woman childbearing potential ) Clinical laboratory test result : Granulocyte count &gt; = 1500/uL ; Platelet count &gt; = 75,000/uL ; Hemoglobin &gt; = 9 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbopoeitin [ Aranesp ( R ) ] permit ) ; Serum bilirubin &lt; = 1.5 ULN ; Alkaline phosphatase , AST , ALT &lt; = 2.5 ULN ( AST , ALT &lt; = 5 ULN subject liver metastasis ) ; Serum creatinine &lt; = 1.5 ULN ; International normalize ratio ( INR ) &lt; = 1.5 activate partial thromboplastin time ( aPTT ) &lt; = 1.5 ULN ( except subject receive anticoagulation therapy ) Prior treatment gemcitabine Two prior regimen treatment platinumresistant disease Two nonplatinumcontaining regimen treatment platinumsensitive disease Prior treatment experimental anticancer agent within 4 week prior Day 1 ( day first study treatment infusion administer ) Prior treatment HER2 pathway inhibitor ( e.g. , Herceptin ( R ) [ trastuzumab ] , Iressa ( R ) [ gefitinib ] , Tarceva &lt; TM &gt; [ erlotinib hydrochloride ] , cetuximab , GW572016 ) History clinical evidence central nervous system brain metastasis Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Prior exposure &gt; 360 mg/m^2 doxorubicin liposomal doxorubicin , &gt; 120 mg/m^2 mitoxantrone , &gt; 90 mg/m^2 idarubicin History malignancy within 5 year Day 1 , except adequately treat carcinoma situ cervix , ductal carcinoma situ ( DCIS ) breast , basal squamous cell skin cancer History serious systemic disease , unstable angina , myocardial infarction within 6 month prior Day 1 treatment , symptom CHF , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia [ i.e. , atrial fibrillation , paroxysmal supraventricular tachycardia ] eligible ) Known HIV infection Pregnancy lactation Major surgery significant traumatic injury within 3 week prior Day 1 treatment Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Omnitarg</keyword>
	<keyword>Cancer</keyword>
	<keyword>Platinum-Resistant</keyword>
</DOC>